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1. Introduction
Human induced pluripotent stem (hiPS) cells are generated with cellular reprogramming
factors [1], and they have the potential to differentiate into a variety of cells. Ethical issues
and graft-versus-host disease may be avoided with hiPS cells because they can be establish‐
ed in each patient individually. hiPS cells may therefore be an ideal cell source for patients.
The liver is a single large organ, the cells of which are 70–80% hepatocytes. These liver-spe‐
cific cells play a major role in protein synthesis, glucose metabolism, and detoxification.
Methods of producing hepatocytes from hiPS cells have been under development for some
time. In this chapter, we will cover the following topics:
• Hepatocyte culture
• Applications of hepatocyte culture
• Production of hepatocytes from human embryonic stem (hES) cells
• Protocols for differentiation of hiPS cells into hepatocytes
• Current applications of hepatocytes differentiated from hiPS cells
• Limitations of differentiation
• Future directions
First we will discuss primary hepatocyte culture. The knowledge on primary hepatocyte cul‐
ture is applicable to maintenance of hepatocytes differentiated from hiPS cells. Next, appli‐
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cation of hepatocyte culture will be discussed because the application would provide
potential usage of hiPS cells. Then production of hepatocytes from ES cells will be present‐
ed. Methods presented in this section are prototypes of differentiation protocols of hiPS cell
into hepatocytes. Sequentially, current protocols of differentiation of hiPS cells into hepato‐
cytes will be summarized. Applications of hepatotyes from hiPS cells will be presented spe‐
cific to human diseases such as hepatitis C virus. Even with the protocols above mentioned,
differentiation of hiPS cells to functioning hepatocytes is difficult. Limitations of differentia‐
tion will be discussed. Finally, potential new approaches will be presented in the last sec‐
tion.
2. Primary hepatocyte culture
Before the era of ES cells or iPS cells, primary hepatocyte culture had been the only method
to investigate differentiation and function of hepatocytes. The accumulated knowledge on
hepatocytes would be applicable to maintain hepatocytes differentiated from hiPS cells.
Hepatocyte culture is useful for developing drugs, cell therapies, and disease models. Pri‐
mary hepatocyte culture is an ideal in vitro model of drug metabolism and toxicology, and
primary hepatocytes can be transplanted into patients with liver failure [2]. Hepatocytes
from patients with metabolic diseases can be used to investigate disease mechanisms. How‐
ever, primary hepatocyte culture remains technically difficult. Hepatocytes are isolated from
a fragment of resected donor liver with a 2-step collagenase perfusion [2]. Fetal hepatocytes
(107 cells) have been transplanted into patients with hepatic encephalopathy [3], and while
the disease improved, there was no increase in survival time. The speculated reason is that
not enough cells were transplanted [4]. Isolated hepatocytes are prone to apoptosis and
damage [5] and have difficulty proliferating once cultured [6]. Primary hepatocyte culture
also presents ethical issues when cells are harvested from humans. Now hiPS cells could
overcome problems that primary hepatocyte culture encounters.
3. Application of hepatocytes differentiated from iPS cells
If hiPS cells could differentiate into hepatocytes, they would be useful for medical practice
and biological study. Potential applications would be as follows:
• Transplantation into patients with hepatic insufficiency
• A method to support patients with hepatic insufficiency such as hemodialysis
• Drug screening
• Toxicology
• In vitro model of hepatitis C virus infection
• In vitro model of hepatocyte differentiation
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• In vitro model of liver diseases
One of  the  most  important  applications  of  hepatocytes  from hiPS cells  would be  trans‐
plantation  into  patients  with  hepatic  insufficiency  caused  by  fulminant  hepatitis.  The
disease  could  be  treated  perfectly  with  transplanted  hepatocytes  because  it  is  caused
by  significant  loss  of  functioning  hepatocytes.  Hepatic  progenitor  cells  have  potential
to  differentiate  into  mature  hepatocytes  and  bile  duct  epithelial  cells.  Hepatic  progeni‐
tor  cells  would  be  expected  to  construct  normal  liver  structure  such  as  hepatic  lobule
and bile  ducts.  Hepatic  progenitor  cells  derived from mouse  embryonic  stem (ES)  cells
engraft  in  host  liver  tissue  and  differentiate  into  hepatocytes  when  transplanted  into
partially  hepatectomized mice  [7].  Hepatocytes  will  also  engraft  in  mice  with  acute  liv‐
er  failure  caused  by  carbon  tetrachloride  intoxication  [8].  This  is  a  promising  finding
that  suggests  that  hepatocytes  from  pluripotent  cells  are  transplantable.  Hepatocytes
have  indeed  been  differentiated  from human ES  cells  and  transplanted  [9].  One  disad‐
vantage  of  the  use  of  human  ES  cells  is  that  they  may  provoke  graft-versus-host  dis‐
ease.  This  could  be  overcome  if  hepatocytes  are  derived  from  iPS  cells  established
from  the  individual  patient.  Patients  with  acute  liver  failure  could  be  successfully
treated in this  manner.
Another application of hepatocytes from hiPS cells would be metabolic diseases. The disease
could be cured with transplantation of functioning hepatocytes because they play pivotal
roles in metabolism. High levels of low-density lipoprotein cholesterol (LDL-Chol) in the
plasma is known to cause cardiovascular disease. Successful reduction of LDL-Chol may
lead to prevention of cardiovascular disease. Mutations in the LDL receptor gene result in
familial hypercholesterolemia (FH); iPS cells derived from patients with FH provide a good
model for analyzing the mechanism of this condition [10].
4. Differentiation of ES cells into hepatocytes
Cultured primary hepatocytes do not proliferate but disappear and lose their function
quickly. Pluripotent stem cells have been focused as a cell source of hepatocytes. Before the
advent of iPS cells, ES cells had been the center of investigation of differentiation methods
into hepatocytes. The topics of the investigation have been growth factors, transcription fac‐
tors, extracellular matrix, and three-dimensional (3D) culture
Mouse ES cells  start  differentiation into the hepatocyte lineage once leukemia inhibitory
factor  (LIF)  is  deprived  and  embryoid  bodies  are  formed  [11-13].  Hepatocyte-like  cells
derived from mouse ES cells take up indocyanine green, express albumin, and form bile
canaliculi  [14].  The induced cells  express specific  live genes such as α-1-antitrypsin and
phosphoenolpyruvate  carboxykinase  (PEPCK).  Withdrawal  of  LIF  is  not  an  appropriate
method for  inducing hiPS cell  differentiation because these  cells  are  not  LIF  dependent
[15].  Human ES  cells  differentiate  into  mesoderm,  endoderm,  and ectoderm after  with‐
drawal of the LIF and basic fibroblast growth factor (bFGF) [16],  but they do not neces‐
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sarily differentiate into hepatocytes. Therefore, growth factors are expected to be needed
for hepatocyte differentiation from human ES cells. Nerve growth factor (NGF) and hep‐
atocyte  growth  factor  (HGF)  induce  differentiation  into  endoderm  and  eventually  liver
cells  [17].  Transcription factors also play an important role in hepatocyte differentiation.
Transcription factor forkhead box protein (Fox) A2 promotes differentiation of mouse ES
cell into the hepatocyte lineage [18], and these hepatocye-like cells express phosphoenol‐
pyruvate (PEPCK) and albumin.
To search for more efficient protocols to promote differentiation of ES cells into hepatoctyes,
combinations of growth factors and extracellular matrices have been investigated [19]. Shira‐
hashi et al. reported that a mixture of Iscove’s modified Dulbecco’s medium with 20% fetal
bovine serum, human insulin, dexamethasone, and type 1 collagen is optimum for mouse
and human ES cell differentiation into the hepatocyte lineage. Bovine serum should not be
used because xeno-proteins are not suitable for human application. This study suggests that
extracellular matrix is important in hepatocyte differentiation.
Hepatic  progenitor  cells  differentiate  into  hepatocytes  in  3D structure  in  liver.  It  is  ex‐
pected that 3D culture is more suitable environment for ES cells to differentiate into hep‐
atocytes.  Indeed,  3D  cultures  of  mouse  ES  cells  have  been  shown  to  differentiate  into
hepatocytes [20]. Embryoid bodies (EB) were inserted into a collagen scaffold 3D culture
system and stimulated with exogenous growth factors and hormones to produce hepatic
differentiation.
Hepatocytes  should  be  isolated  from  the  other  cells  because  ES  cells  could  be  among
hepatocytes. Undifferentiated cells have been shown to form teratoma when transplanted
into  recipient  cells  mixed with  hepatocytes  [21].  A  practical  method to  avoid  this  is  to
enrich  the  hepatocytes  and eliminate  the  undifferentiated cells  by  Percoll  discontinuous
gradient centrifugation [22, 23].
Rambhatla et al. [24] reported that the addition of sodium butylate leads to significant cell
death and induction of hepatocyte differentiation in human ES cells. Cells cultured with so‐
dium butylate express albumin, α-1-antitrypsin, and cytochrome P450 and also accumulate
glycogen. However, the induced cells do not express alpha-fetoprotein (AFP). Sodium buty‐
late is a possible candidate for a small molecule to eliminate undifferentiated cells and in‐
duce hepatic differentiation.
5. Protocols for differentiation of hiPS cells into hepatocytes
Protocols for differentiation of hiPS cells into hepatocytes follow those for mouse ES cells as
mentioned above. Stepwise protocols are currently used to promote the differentiation
[25-28] (Table 1). These protocols consist of sequential application of growth factors and in‐
troduction of transcription factors to mimic hepatocyte differentiation during liver develop‐
ment. The progression is endodermal cell, immature hepatocyte (often referred as
hepatoblast), and finally mature hepatocyte.
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DeLaForest [25] D0-5 D5-10 D10-15 D15-20
Activin A, LY294002 BMP4, FGF2 HGF OncoM
S-Tayeb [26] D0-5 D5-10 D10-15 D15-20
O2: 20% O2: 4% O2: 4% O2: 20%
Activin A BMP4, FGF2 HGF OncoM
Song [27] D0-3 D4-7 D8-13 D14-18 D19-21
Activin A FGF4, BMP3 HGF, KGF OncoM OncoM, Dex
D: day; BMP4: bone morphogenic protein 4; FGF: fibroblast growth factor 2; HGF: hepatocyte growth factor; OncoM:
oncostatin M; KGF: keratinocyte growth factor; Dex: dexamethasone.
Table 1. Protocols for hepatocyte differentiation from human induced pluripotent stem cells.
6. Endodermal differentiation
All differentiation protocols apply activin A (a member of the tumor growth factor β super‐
family) at a high concentration of 100-ng/mL. LY294002 (a specific inhibitor of phosphatidyl-
inositol 3 phosphatase), B27 supplement, or bFGF are added, depending on the purpose of
the research. After 3–5 days of culture, iPS cells differentiate into endodermal cells. From
days 5–10, a combination of bone morphogens 2 or 4 and fibroblast growth factors 2 or 4 is
applied. Takayama et al. [28] introduced sex-determining region Y box 17 to promote differ‐
entiation at this stage after incubation with activin A. Sekine et al. [29] used LY294002 in ad‐
dition to 100-ng/mL activin A. In their study, FoxA2 and Sox17 expressions appeared but
AFP and albumin were not analyzed. Phosphatidyl inositol (PI) 3 kinase may control differ‐
entiation of iPS cells into endodemal cells, but other factors are still needed.
7. Differentiation into immature hepatocytes
Hepatocyte growth factor (HGF) or keratinocyte growth factor (KGF) is applied from days
10–14. Inamura et al. introduced hematopoietically expressed homeobox (HEX) to promote
differentiation into hepatoblasts [30].
8. Differentiation into mature hepatocytes
HGF or oncostatin M is added to promote differentiation of hepatoblasts into mature hepa‐
tocytes. Takayama et al. [28] introduced hepatocyte nuclear factor-4 to provide the terminal
differentiation of hepatoblasts into hepatocytes. Mature hepatocytes appeared at approxi‐
mately 20 days after the initiation of the differentiation process. Si-Tayeb et al. [26] cultured
cells under 4% oxygen from days 5 to 15.
In another study, Nakamura et al. [31] derived hepatocytes from human ES and iPS cells un‐
der feeder- and serum-free conditions. They succeeded in producing cholangiocytes and
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proliferating progenitors. The cells produced with their protocol were confirmed to function
as mature hepatocytes. Indocyanine green was taken up by 30% of the hepatocytes, and 80%
stored glycogen. They also maintained the metabolic activity of CYP3A4.
Chen et al. [32] proposed another multistep protocol. They do not apply any transcription
factors, but growth factors. They have succeeded in differentiation of hiPS cells into mature
hepatocytes within only 12 days. The period is significantly shorter than the other research‐
ers. With their method, activin A (100 ng/mL) and HGF (10 ng/mL) were added from days 1
to 3, and prior to that, HGF had been added at the last step of hepatocyte maturation. They
also added HGF at the first step of differentiation and successfully derived hepatocyte-like
cells. Sox17 and FoxA2, induced by activin A, are important markers of endodermal differ‐
entiation. HGF and activin A may have synergistic effects on the differentiating cells.
Transcription factors play an important role in liver development and hepatocyte differentia‐
tion [33]. Generally, pluripotent stem cells are hard to transfect plasmids. Adenovirus vectors
provide highly efficient transduction to hiPS cells [34]. Inamura et al. [30] transduced HEX into
hES and hiPS cells to efficiently produce hepatoblasts (Table 2). After differentiation into hepa‐
toblasts, transduction of HNF4α finally produces mature hepatocytes [28].
Inamura [34] D0-6 D6-8 D9-18
Activin A BMP4, FGF4 FGF4, HGF, OncoM, Dex
D5: passage, D6:Ad-Hex D9: passage
Takayama [28] D0-3 D3-6 D7-9 D10-20
Activin A Activin A BMP4, FGF4 HGF, OncoM, Dex
D3: Ad-Sox17 D5: passage, D6: Ad-Hex D9: Ad-HNF4A
BMP4: bone morphogen protein 4; FGF4: fibroblast growth factor 4; HGF: hepatocyte growth factor; OncoM: oncosta‐
tin M; Dex: dexamethasone; Ad-Hex, Sox17, HNF4A: adenovirus vector transducing Hex, Sox17, and HNF4A, respec‐
tively; Hex: hematopoietically expressed homeobox; Sox17: sex determining region Y box 7; HNF4A: hepatocyte
nuclear factor 4 α.
Table 2. Protocols for hepatocyte differentiation from human induced pluripotent stem cells with adenovirus vectors.
9. Current applications of hepatocytes differentiated from hiPS cells
Hepatocytes from hiPS cells are perfect for in vitro model of human diseases because human
primary hepatocytes have both ethical and technical issues. Hepatitis C virus (HCV) causes
liver cirrhosis and hepatocellular carcinoma (HCC). Primary human hepatocyte culture is a
relevant in vitro model for HCV infection, but it presents some ethical issues. Human iPS
cells are not permissive to HCV. Interestingly, hepatocyte-like cells derived from hiPS cells
recapitulate permissiveness and are infected with HCV [35, 36]. Hepatocyte-like cells de‐
rived from hiPS cells exert an inflammatory response to infection [37] and may provide a
suitable in vitro model to study the mechanism of HCV infection. Such a model may poten‐
tially lead to innovative methods to inhibit HCV and prevent liver cirrhosis and HCC.
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Hepatocyte-like cells derived from mouse iPS cells have been shown to improve acute liver
failure caused by carbon tetrachloride [38]. These cells were transplanted through peritoneal
injection and significantly reduced the extent of necrotic liver. The authors concluded that
the hepatoprotective effects were based on antioxidant activity.
10. Limitations of hepatocytes differentiated from hiPS cells
Cells cultured under the protocols mentioned above are referred to as hepatocyte-like cells.
In these cells, detoxification activity is lower than in primary hepatocyte culture [26, 28].
Hepatocytes differentiated from hiPS cells have lower expression levels of FoxA1, FoxA2,
FoxA3, and HNF1α, and Takayama et al. [28] speculated that other factors are still needed.
iPS cells retain their donor cell gene expressions. Lee et al. [35] generated mouse iPS cells
from hepatoblasts and adult hepatocytes. Hepatocytes differentiated from hiPS cells express
mRNA that is normally not found in fetal or adult liver [25]. An interesting finding is that
hepatocytes are differentiated more efficiently from hepatoblast-derived iPS cells than from
adult hepatocytes. This suggests that the efficiency of hepatocyte differentiation may de‐
pend on the origin of the iPS cells. Protocols need to be further developed given that the
mentioned liver-specific genes are important for clinical and pharmacological applications.
11. Future directions
To overcome these limitations, novel approaches are under investigation. Current research
efforts can be categorized into extracellular matrix, 3D culture, and cell sheet approaches.
An extracellular matrix (ECM) provides conditions suitable for cultured cells to differentiate
to hepatocytes. M15, a mesonephric cell line, induces differentiation of mouse ES cells into
the hepatocyte lineage [39]. Eighty percent of mouse ES cells cultured with M15 express
AFP, and 9% express albumin. It is interesting that even the fixed M15 cells can promote
mouse ES cell differentiation. Shiraki et al. reported a synthesized basement membrane com‐
posed of human recombinant laminin 511 [40] that induced differentiation of mouse ES cells
into hepatocyte lineages.
A 3D culture system is composed of gelatin and extracellular matrix from Swiss 3T3 cells
[41]. This system preserves the functions of hepatocyte-like cells differentiated from hiPS
cells. The most important component of the ECM has been determined to be type 1 collagen.
Cells are 3D cultured in hollow fibers similar to embryoid bodies. Hollow fibers are useful
because the efficiency of embryoid body formation is low compared with mouse ES cells,
which also differentiate into hepatocytes in hollow fibers [42]. The organoid culture system
efficiently allows mouse ES cells to form cellular aggregates in their lumen. Liver-specific
functions of mouse ES cells are comparable with those of primary hepatocytes.
Primary rat hepatocytes have been successfully cultured for 200 days on temperature-respon‐
sive sheets [43]. These sheets attach on the bottoms of culture dishes at 37ºC and detach at 25ºC.
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They provide easy culturing and handling of cells. Primary rat hepatocytes have preserved liv‐
er-specific functions for 28 days in hybrid sheets with endothelial cells [44]. This system ena‐
bles easy manipulation of iPS cells and may promote differentiation into hepatocytes.
12. Conclusion
Human iPS cells are a promising source for hepatocytes and may be used for drug screen‐
ing, for cell transplantation, and as a model for studying human diseases. Protocols have
been presented for the differentiation of human iPS cells into hepatocytes; however, the dif‐
ferentiated cells have limited hepatocyte characteristics. In the future, as more sophisticated
methods are expected to be developed, new applications of these cells will be realized.
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